Increased IL-31 expression in serum and tissue protein in prurigo nodularis

Background: Prurigo nodularis (PN) is a chronic pruritic skin disease which can greatly impact patients’ quality of life. Moreover, the pathogenesis remains unclear, making it a difficult-to-treat condition. Aims: To investigate the expression of interleukin-31 (IL-31) in serum and skin biopsy specimens of PN patients and healthy subjects and identify its possible correlation to disease severity and itch intensity. Methods: Patients with PN and healthy volunteers were recruited for the study. Expression levels of IL-31 were measured by enzyme-linked immunosorbent assay and immunohistochemistry. Baseline characteristics, disease activity, itch intensity, and related laboratory results were collected. Results: Forty-three PN patients and 31 healthy subjects participated in our study. The PN patients had significantly higher mean serum IL-31 levels than the healthy subjects (52.9 ± 18.2 versus 36.3 ± 10.7 pg/ml, p < 0.001). Epidermal and dermal PN lesions also exhibited significantly higher IL-31 expression compared with the healthy skin (p < 0.001 and p = 0.01, respectively). However, there was no significant difference in serum or lesional expression of IL-31 by disease severity or itch intensity. Conclusion: Increased IL-31 expression in serum and PN lesions suggests that IL-31 has a potential role in the pathogenesis of PN.

[1]  J. Paolini,et al.  Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta , 2021, Experimental dermatology.

[2]  C. Foocharoen,et al.  Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms , 2020, Heliyon.

[3]  K. Sawanyawisuth,et al.  Interleukin-31 and Chronic Pruritus of Unknown Origin , 2020, Biomarker insights.

[4]  F. Wang,et al.  Itch: A Paradigm of Neuroimmune Crosstalk. , 2020, Immunity.

[5]  M. Dugas,et al.  Chronic nodular prurigo: clinical profile and burden. A European cross‐sectional study , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  T. Bieber,et al.  Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. , 2020, The New England journal of medicine.

[7]  S. Ständer,et al.  Diagnostic and Treatment Algorithm for Chronic Nodular Prurigo. , 2020, Journal of the American Academy of Dermatology.

[8]  Wei Yue,et al.  Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol. , 2019, Bio-protocol.

[9]  Jie Chen,et al.  Serum levels of IL-31, IL-33 and ST2 in allergic rhinitis of children in China. , 2018, Cellular and molecular biology.

[10]  S. Ständer,et al.  Prurigo Nodularis and Its Management. , 2018, Dermatologic clinics.

[11]  K. Kabashima,et al.  Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis , 2018, Experimental dermatology.

[12]  S. Gangemi,et al.  IL-33/IL-31 Axis: A Potential Inflammatory Pathway , 2018, Mediators of inflammation.

[13]  T. Ruzicka,et al.  IL‐31: A new key player in dermatology and beyond , 2018, The Journal of allergy and clinical immunology.

[14]  Min Chen,et al.  Interleukin-31 expression and relation to disease severity in human asthma , 2016, Scientific Reports.

[15]  Z. Adamski,et al.  Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations , 2015, Postepy dermatologii i alergologii.

[16]  M. Gilliet,et al.  Prurigo nodularis: retrospective study of 13 cases managed with methotrexate , 2014, Clinical and experimental dermatology.

[17]  T. Hawro,et al.  Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients , 2012, Archives of Dermatological Research.

[18]  R. Fölster-Holst,et al.  IL‐31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis , 2012, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[19]  L. French,et al.  IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. , 2012, Acta dermato-venereologica.

[20]  B. Lüscher,et al.  IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. , 2012, Acta dermato-venereologica.

[21]  Jun-Mo Yang,et al.  IL-31 Serum Protein and Tissue mRNA Levels in Patients with Atopic Dermatitis , 2011, Annals of dermatology.

[22]  Tomoko Mori,et al.  Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. , 2011, European journal of dermatology : EJD.

[23]  S. Ständer,et al.  Correlation of IL-31 serum levels with severity of atopic dermatitis. , 2008, The Journal of allergy and clinical immunology.

[24]  M. Steinhoff,et al.  IL-31: a new link between T cells and pruritus in atopic skin inflammation. , 2006, The Journal of allergy and clinical immunology.

[25]  B. Harder,et al.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.